Login to Your Account



Clinic Roundup


Monday, March 14, 2011
Senesco Technologies Inc., of New Brunswick, N.J., said the FDA put the firm's planned study of SNS01-T in multiple myeloma on hold until the drug master file of one of its suppliers is updated. No other issues were raised with the firm's investigational new drug application, and Senesco plans to start the studies in the first half of this year. SNS01-T is designed to regulate a growth control switch that induces apoptosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription